請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55198完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃銓珍(Chang-Jen Huang) | |
| dc.contributor.author | Ming-Wu Feng | en |
| dc.contributor.author | 馮明五 | zh_TW |
| dc.date.accessioned | 2021-06-16T03:50:58Z | - |
| dc.date.available | 2020-03-13 | |
| dc.date.copyright | 2015-03-13 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-01-20 | |
| dc.identifier.citation | Abraham, R.T., Wiederrecht, G.J., 1996. Immunopharmacology of rapamycin. Annual review of immunology 14, 483-510.
Alberts, A.W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., et al., 1980. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences of the United States of America 77, 3957-3961. Amsterdam, A., Hopkins, N., 2006. Mutagenesis strategies in zebrafish for identifying genes involved in development and disease. Trends in genetics : TIG 22, 473-478. Anderson, K.M., Castelli, W.P., Levy, D., 1987. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA : the journal of the American Medical Association 257, 2176-2180. Andre, M., Ando, S., Ballagny, C., Durliat, M., Poupard, G., Briancon, C., Babin, P.J., 2000. Intestinal fatty acid binding protein gene expression reveals the cephalocaudal patterning during zebrafish gut morphogenesis. The International journal of developmental biology 44, 249-252. Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., et al., 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278. Ballantyne, C.M., Corsini, A., Davidson, M.H., Holdaas, H., Jacobson, T.A., Leitersdorf, E., Marz, W., Reckless, J.P., Stein, E.A., 2003. Risk for myopathy with statin therapy in high-risk patients. Archives of internal medicine 163, 553-564. Bassett, D.I., Bryson-Richardson, R.J., Daggett, D.F., Gautier, P., Keenan, D.G., Currie, P.D., 2003. Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development 130, 5851-5860. Bassett, D.I., Currie, P.D., 2003. The zebrafish as a model for muscular dystrophy and congenital myopathy. Human molecular genetics 12 Spec No 2, R265-270. Berland, Y., Coponat, H.V., Durand, C., Baz, M., Laugier, R., Musso, J.L., 1991. Rhabdomyolysis with Simvastatin Use. Nephron 57, 365-366. Betz, C., Stracka, D., Prescianotto-Baschong, C., Frieden, M., Demaurex, N., Hall, M.N., 2013. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proceedings of the National Academy of Sciences of the United States of America 110, 12526-12534. Bhatnagar, D., Soran, H., Durrington, P.N., 2008. Hypercholesterolaemia and its management. Bmj 337, a993. Birjmohun, R.S., Hutten, B.A., Kastelein, J.J., Stroes, E.S., 2005. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 45, 185-197. Bottorff, M., Hansten, P., 2000. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Archives of internal medicine 160, 2273-2280. Brannen, K.C., Panzica-Kelly, J.M., Danberry, T.L., Augustine-Rauch, K.A., 2010. Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. Birth defects research. Part B, Developmental and reproductive toxicology 89, 66-77. Brewer, H.B., Jr., 2003. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. The American journal of cardiology 92, 23K-29K. Brown, A.G., Smale, T.C., King, T.J., Hasenkamp, R., Thompson, R.H., 1976. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. Journal of the Chemical Society. Perkin transactions 1, 1165-1170. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., Schreiber, S.L., 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758. Brown, E.J., Beal, P.A., Keith, C.T., Chen, J., Shin, T.B., Schreiber, S.L., 1995. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446. Brown, M.S., Goldstein, J.L., 1979. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proceedings of the National Academy of Sciences of the United States of America 76, 3330-3337. Bruckert, E., Hayem, G., Dejager, S., Yau, C., Begaud, B., 2005. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 19, 403-414. Bruckert, E., Labreuche, J., Amarenco, P., 2010. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361. Brunn, G.J., Hudson, C.C., Sekulic, A., Williams, J.M., Hosoi, H., Houghton, P.J., Lawrence, J.C., Jr., Abraham, R.T., 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101. Bultynck, G., De Smet, P., Rossi, D., Callewaert, G., Missiaen, L., Sorrentino, V., De Smedt, H., Parys, J.B., 2001. Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor. The Biochemical journal 354, 413-422. Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H., Sabatini, D.M., 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proceedings of the National Academy of Sciences of the United States of America 95, 1432-1437. Cafferkey, R., Young, P.R., McLaughlin, M.M., Bergsma, D.J., Koltin, Y., Sathe, G.M., Faucette, L., Eng, W.K., Johnson, R.K., Livi, G.P., 1993. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Molecular and cellular biology 13, 6012-6023. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A., Skene, A.M., et al., 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine 350, 1495-1504. Cao, P., Hanai, J., Tanksale, P., Imamura, S., Sukhatme, V.P., Lecker, S.H., 2009. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 23, 2844-2854. Chambraud, B., Radanyi, C., Camonis, J.H., Shazand, K., Rajkowski, K., Baulieu, E.E., 1996. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. The Journal of biological chemistry 271, 32923-32929. Chan, S., 2004. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. British journal of cancer 91, 1420-1424. Childs, S., Weinstein, B.M., Mohideen, M.A., Donohue, S., Bonkovsky, H., Fishman, M.C., 2000. Zebrafish dracula encodes ferrochelatase and its mutation provides a model for erythropoietic protoporphyria. Current biology : CB 10, 1001-1004. Choi, J., Chen, J., Schreiber, S.L., Clardy, J., 1996. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242. Cholesterol Treatment Trialists, C., 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 380, 581-590. Chou, M.M., Blenis, J., 1995. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Current opinion in cell biology 7, 806-814. Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Bracs, P., et al., 1997. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. The American journal of cardiology 80, 39-44. Davidson, M.H., Stein, E.A., Dujovne, C.A., Hunninghake, D.B., Weiss, S.R., Knopp, R.H., Illingworth, D.R., Mitchel, Y.B., Melino, M.R., Zupkis, R.V., et al., 1997. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. The American journal of cardiology 79, 38-42. Dayton, S., Chapman, J.M., Pearce, M.L., Popjak, G.J., 1970. Cholesterol, atherosclerosis, ischemic heart disease, and stroke. Annals of internal medicine 72, 97-109. Dietschy, J.M., Wilson, J.D., 1970a. Regulation of cholesterol metabolism. The New England journal of medicine 282, 1179-1183. Dietschy, J.M., Wilson, J.D., 1970b. Regulation of cholesterol metabolism. 3. The New England journal of medicine 282, 1241-1249. Dietschy, J.M., Wilson, J.D., 1970c. Regulation of cholesterol metabolism. I. The New England journal of medicine 282, 1128-1138. Ding, Y., Sun, X., Huang, W., Hoage, T., Redfield, M., Kushwaha, S., Sivasubbu, S., Lin, X., Ekker, S., Xu, X., 2011. Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circulation research 109, 658-669. Dopazo, C., Bilbao, I., Lazaro, J.L., Sapisochin, G., Caralt, M., Blanco, L., Castells, L., Charco, R., 2009. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplantation proceedings 41, 1021-1024. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M., Jr., 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA : the journal of the American Medical Association 279, 1615-1622. Dreyfus, J.C., Schapira, G., Demos, J., 1960. [Study of serum creatine kinase in myopathic patients and their families]. Revue francaise d'etudes cliniques et biologiques 5, 384-386. Duff, C.J., Scott, M.J., Kirby, I.T., Hutchinson, S.E., Martin, S.L., Hooper, N.M., 2009. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. The Biochemical journal 419, 577-584. Durrington, P., 2003. Dyslipidaemia. Lancet 362, 717-731. Endo, A., 2004. The origin of the statins. 2004. Atherosclerosis. Supplements 5, 125-130. Endo, A., Kuroda, M., Tsujita, Y., 1976. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. The Journal of antibiotics 29, 1346-1348. Endo, A., Tsujita, Y., Kuroda, M., Tanzawa, K., 1977. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. European journal of biochemistry / FEBS 77, 31-36. Fernandez, D., Bonilla, E., Mirza, N., Niland, B., Perl, A., 2006. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis and rheumatism 54, 2983-2988. Fernandez, G., Spatz, E.S., Jablecki, C., Phillips, P.S., 2011. Statin myopathy: a common dilemma not reflected in clinical trials. Cleveland Clinic journal of medicine 78, 393-403. Fernandez Zatarain, G., Navarro, V., Garcia, H., Villatoro, J., Calvo, C., 1994. Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron 66, 483-484. Fishman, M.C., Stainier, D.Y., Breitbart, R.E., Westerfield, M., 1997. Zebrafish: genetic and embryological methods in a transparent vertebrate embryo. Methods in cell biology 52, 67-82. Flint, O.P., Masters, B.A., Gregg, R.E., Durham, S.K., 1997. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicology and applied pharmacology 145, 91-98. Franc, S., Dejager, S., Bruckert, E., Chauvenet, M., Giral, P., Turpin, G., 2003. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 17, 459-465. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., Racie, T.S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al., 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America 105, 11915-11920. Franklin, M.R., 1991. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in enzymology 206, 559-573. Fuhrmans, V., 2002. Bayer discloses higher death toll from Baycol. Wall Street J 21, A10-A10. Fujii, J., Otsu, K., Zorzato, F., de Leon, S., Khanna, V.K., Weiler, J.E., O'Brien, P.J., MacLennan, D.H., 1991. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253, 448-451. Furberg, C.D., Pitt, B., 2001. Withdrawal of cerivastatin from the world market. Current controlled trials in cardiovascular medicine 2, 205-207. Gaddi, A., Arca, M., Ciarrocchi, A., Fazio, S., D'Alo, G., Tiozzo, R., Descovich, G.C., Calandra, S., 1991. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS. Metabolism: clinical and experimental 40, 1074-1078. Ginsberg, H.N., Le, N.A., Short, M.P., Ramakrishnan, R., Desnick, R.J., 1987. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. The Journal of clinical investigation 80, 1692-1697. Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., Goldberg, A.L., 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 98, 14440-14445. Graham, D.J., Staffa, J.A., Shatin, D., Andrade, S.E., Schech, S.D., La Grenade, L., Gurwitz, J.H., Chan, K.A., Goodman, M.J., Platt, R., 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA : the journal of the American Medical Association 292, 2585-2590. Hallare, A., Nagel, K., Kohler, H.R., Triebskorn, R., 2006. Comparative embryotoxicity and proteotoxicity of three carrier solvents to zebrafish (Danio rerio) embryos. Ecotoxicology and environmental safety 63, 378-388. Hammerschmidt, M., Blader, P., Strahle, U., 1999. Strategies to perturb zebrafish development. Methods in cell biology 59, 87-115. Hanai, J., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P.S., Sukhatme, V.P., et al., 2007. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. The Journal of clinical investigation 117, 3940-3951. Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Nadon, N.L., Wilkinson, J.E., Frenkel, K., Carter, C.S., et al., 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395. Hashim, S.A., Vanitallie, T.B., 1965. Cholestyramine Resin Therapy for Hypercholesteremia: Clinical and Metabolic Studies. JAMA : the journal of the American Medical Association 192, 289-293. Heart Protection Study Collaborative, G., 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22. Hill, A.J., Teraoka, H., Heideman, W., Peterson, R.E., 2005. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicological sciences : an official journal of the Society of Toxicology 86, 6-19. Hoeg, J.M., Brewer, H.B., Jr., 1987. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA : the journal of the American Medical Association 258, 3532-3536. Hoffman, W.F., Alberts, A.W., Anderson, P.S., Chen, J.S., Smith, R.L., Willard, A.K., 1986. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. Journal of medicinal chemistry 29, 849-852. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., Burnett, J.R., 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193, 445-448. Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., Humphray, S., McLaren, K., Matthews, L., et al., 2013. The zebrafish reference genome sequence and its relationship to the human genome. Nature 496, 498-503. Huang, C.C., Chen, P.C., Huang, C.W., Yu, J., 2007. Aristolochic Acid induces heart failure in zebrafish embryos that is mediated by inflammation. Toxicological sciences : an official journal of the Society of Toxicology 100, 486-494. Huang, S., Bjornsti, M.A., Houghton, P.J., 2003. Rapamycins: mechanism of action and cellular resistance. Cancer biology & therapy 2, 222-232. Huang, S.H., Hsiao, C.D., Lin, D.S., Chow, C.Y., Chang, C.J., Liau, I., 2011. Imaging of zebrafish in vivo with second-harmonic generation reveals shortened sarcomeres associated with myopathy induced by statin. PloS one 6, e24764. Imagawa, T., Smith, J.S., Coronado, R., Campbell, K.P., 1987. Purified ryanodine receptor from skeletal muscle sarcoplasmic reticulum is the Ca2+-permeable pore of the calcium release channel. The Journal of biological chemistry 262, 16636-16643. Istvan, E., 2003. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis. Supplements 4, 3-8. Kaftan, E., Marks, A.R., Ehrlich, B.E., 1996. Effects of rapamycin on ryanodine receptor/Ca(2+)-release channels from cardiac muscle. Circulation research 78, 990-997. Kannel, W.B., Castelli, W.P., Gordon, T., McNamara, P.M., 1971. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Annals of internal medicine 74, 1-12. Kaufmann, P., Torok, M., Zahno, A., Waldhauser, K.M., Brecht, K., Krahenbuhl, S., 2006. Toxicity of statins on rat skeletal muscle mitochondria. Cellular and molecular life sciences : CMLS 63, 2415-2425. Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P., Sabatini, D.M., 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175. Kong, J.Y., Rabkin, S.W., 2004. Cytoskeletal actin degradation induced by lovastatin in cardiomyocytes is mediated through caspase-2. Cell biology international 28, 781-790. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N.R., Hall, M.N., 1993. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73, 585-596. Lagace, T.A., Curtis, D.E., Garuti, R., McNutt, M.C., Park, S.W., Prather, H.B., Anderson, N.N., Ho, Y.K., Hammer, R.E., Horton, J.D., 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. The Journal of clinical investigation 116, 2995-3005. Lalanne, F., Lambert, G., Amar, M.J., Chetiveaux, M., Zair, Y., Jarnoux, A.L., Ouguerram, K., Friburg, J., Seidah, N.G., Brewer, H.B., Jr., et al., 2005. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. Journal of lipid research 46, 1312-1319. Lambert, G., Sjouke, B., Choque, B., Kastelein, J.J., Hovingh, G.K., 2012. The PCSK9 decade. Journal of lipid research 53, 2515-2524. Laplante, M., Sabatini, D.M., 2012. mTOR signaling in growth control and disease. Cell 149, 274-293. Lieschke, G.J., Currie, P.D., 2007. Animal models of human disease: zebrafish swim into view. Nature reviews. Genetics 8, 353-367. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S.Y., et al., 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128. Magnuson, B., Ekim, B., Fingar, D.C., 2012. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. The Biochemical journal 441, 1-21. Makky, K., Tekiela, J., Mayer, A.N., 2007. Target of rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine. Developmental biology 303, 501-513. Mitch, W.E., Goldberg, A.L., 1996. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. The New England journal of medicine 335, 1897-1905. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O'Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., et al., 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. The New England journal of medicine 349, 1315-1323. Nambudiri, A.M., Ranganathan, S., Rudney, H., 1980. The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts. The Journal of biological chemistry 255, 5894-5899. Nasevicius, A., Ekker, S.C., 2000. Effective targeted gene 'knockdown' in zebrafish. Nature genetics 26, 216-220. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., Crowe, T., Howard, G., Cooper, C.J., Brodie, B., et al., 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA : the journal of the American Medical Association 291, 1071-1080. Omar, M.A., Wilson, J.P., 2002. FDA adverse event reports on statin-associated rhabdomyolysis. The Annals of pharmacotherapy 36, 288-295. Omar, M.A., Wilson, J.P., Cox, T.S., 2001. Rhabdomyolysis and HMG-CoA reductase inhibitors. The Annals of pharmacotherapy 35, 1096-1107. Pedersen, T.R., Tobert, J.A., 1996. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug safety : an international journal of medical toxicology and drug experience 14, 11-24. Peterson, R.T., Link, B.A., Dowling, J.E., Schreiber, S.L., 2000. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proceedings of the National Academy of Sciences of the United States of America 97, 12965-12969. Piotrowski, T., Ahn, D.G., Schilling, T.F., Nair, S., Ruvinsky, I., Geisler, R., Rauch, G.J., Haffter, P., Zon, L.I., Zhou, Y., et al., 2003. The zebrafish van gogh mutation disrupts tbx1, which is involved in the DiGeorge deletion syndrome in humans. Development 130, 5043-5052. Powers, R.W., 3rd, Kaeberlein, M., Caldwell, S.D., Kennedy, B.K., Fields, S., 2006. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes & development 20, 174-184. Rabkin, S.W., Kong, J.Y., 2003. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicology and applied pharmacology 193, 346-355. Rios, E., Pizarro, G., 1991. Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiological reviews 71, 849-908. Roberts, W.C., 1997. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. The American journal of cardiology 80, 106-107. Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., Snyder, S.H., 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43. Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont, F.J., Wiederrecht, G., Abraham, R.T., 1995. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. The Journal of biological chemistry 270, 815-822. Safeer, R.S., Lacivita, C.L., 2000. Choosing drug therapy for patients with hyperlipidemia. American family physician 61, 3371-3382. Sandow, A., 1952. Excitation-contraction coupling in muscular response. The Yale journal of biology and medicine 25, 176-201. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L., Sabatini, D.M., 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular cell 22, 159-168. Schagger, H., von Jagow, G., 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Analytical biochemistry 166, 368-379. Seidah, N.G., Prat, A., 2012. The biology and therapeutic targeting of the proprotein convertases. Nature reviews. Drug discovery 11, 367-383. Shan, L., Pang, L., Zhang, R., Murgolo, N.J., Lan, H., Hedrick, J.A., 2008. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochemical and biophysical research communications 375, 69-73. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J., 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England journal of medicine 333, 1301-1307. Sheridan, C., 2013. Phase 3 data for PCSK9 inhibitor wows. Nature biotechnology 31, 1057-1058. Siekierka, J.J., Hung, S.H., Poe, M., Lin, C.S., Sigal, N.H., 1989. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341, 755-757. Silva, M., Matthews, M.L., Jarvis, C., Nolan, N.M., Belliveau, P., Malloy, M., Gandhi, P., 2007. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clinical therapeutics 29, 253-260. Solnica-Krezel, L., Schier, A.F., Driever, W., 1994. Efficient recovery of ENU-induced mutations from the zebrafish germline. Genetics 136, 1401-1420. Spence, R., Gerlach, G., Lawrence, C., Smith, C., 2008. The behaviour and ecology of the zebrafish, Danio rerio. Biological reviews of the Cambridge Philosophical Society 83, 13-34. Staffa, J.A., Chang, J., Green, L., 2002. Cerivastatin and reports of fatal rhabdomyolysis. The New England journal of medicine 346, 539-540. Streisinger, G., Walker, C., Dower, N., Knauber, D., Singer, F., 1981. Production of clones of homozygous diploid zebra fish (Brachydanio rerio). Nature 291, 293-296. Summerton, J., Weller, D., 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense & nucleic acid drug development 7, 187-195. Tobert, J.A., 1988. Efficacy and long-term adverse effect pattern of lovastatin. The American journal of cardiology 62, 28J-34J. Tobin, J.L., Beales, P.L., 2008. Restoration of renal function in zebrafish models of ciliopathies. Pediatric nephrology 23, 2095-2099. Tonkin, A., Aylward, P., Colquhoun, D., Glasziou, P., Harris, P., MacMahon, S., Magnus, P., Newel, D., Nestel, P., Sharpe, N., et al., 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. The New England journal of medicine 339, 1349-1357. Urso, M.L., Clarkson, P.M., Hittel, D., Hoffman, E.P., Thompson, P.D., 2005. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arteriosclerosis, thrombosis, and vascular biology 25, 2560-2566. Vanholder, R., Sever, M.S., Erek, E., Lameire, N., 2000. Rhabdomyolysis. Journal of the American Society of Nephrology : JASN 11, 1553-1561. Vezina, C., Kudelski, A., Sehgal, S.N., 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. The Journal of antibiotics 28, 721-726. Wallace, C.S., Mueller, B.A., 1992. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. The Annals of pharmacotherapy 26, 190-192. Wang, T., Donahoe, P.K., Zervos, A.S., 1994. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science 265, 674-676. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., Lowe, S.W., 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337. Wierzbicki, A.S., 2004. Lipid-altering agents: the future. International journal of clinical practice 58, 1063-1072. Wu, S., Ibarra, M.C., Malicdan, M.C., Murayama, K., Ichihara, Y., Kikuchi, H., Nonaka, I., Noguchi, S., Hayashi, Y.K., Nishino, I., 2006. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain : a journal of neurology 129, 1470-1480. Xiang, J., Yang, H., Che, C., Zou, H., Yang, H., Wei, Y., Quan, J., Zhang, H., Yang, Z., Lin, S., 2009. Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays. PloS one 4, e4361. Yip, C.K., Murata, K., Walz, T., Sabatini, D.M., Kang, S.A., 2010. Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition. Molecular cell 38, 768-774. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., Kinch, L., Grishin, N.V., Horton, J.D., Cohen, J.C., Hobbs, H.H., 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. American journal of human genetics 79, 514-523. Zucchi, R., Ronca-Testoni, S., 1997. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacological reviews 49, 1-51. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55198 | - |
| dc.description.abstract | HMG-CoA reductase抑制劑，又被稱為statins，被廣泛用於治療高膽固醇血症(hypercholesterolemia)。然而，這類藥物會導致一系列肌肉相關的副作用，並且副作用與用量有劑量效應 (dose-dependent) 關係。這些症狀包含較輕微的肌痛 (myalgia)、肌炎 (myositis) 及嚴重的橫紋肌溶解症 (rhabdomyolysis)。雖然橫紋肌溶解症發生的比率不高，但有報告指出，對一名肝臟移植患者同時施以Simvastatin與免疫抑制劑Rapamycin時，引發了致死性橫紋肌溶解症。
在本實驗中，我們建立了一個以statin誘發肌肉病變 (myopathy) 的斑馬魚模型。首先，比較Simvastatin、Atorvastatin和Lovastatin引發肌肉病變的效果，並選出Simvastatin進行進一步分析，發現處理時間、濃度與肌肉病變有正向關係。接著在進行Rapamycin與Simvastatin共同處理時，卻發現Rapamycin能抑制肌肉病變現象。由於Rapamycin主要的功能是抑制TOR (target of rapamycin) 的活性，為了確認其對肌肉病變的保護能力是否與TOR有關，我們另外使用morpholino (MO) 將TOR基因knockdown。結果注射tor MO的胚胎在Simvastatin處理後依舊產生肌肉病變，而對注射tor MO的胚胎以Rapamycin 與Simvastatin共同處理仍能防止肌肉病變。由此推論，Rapamycin可能不是透過抑制TOR而達到對肌肉病變的保護效果。 | zh_TW |
| dc.description.abstract | HMG-CoA reductase inhibitors, also known as statins, are widely used to treat hypercholesterolemia. However, they can lead to a number of dose-dependent and muscle-associated side effects, ranging from myalgia to myositis and rhabdomyolysis. The frequency of rhabdomyolysis incidence is low, however, it is reported that concomitant use of Simvastatin with Rapamycin, an immunosuppressor which inhibits TOR (target of rapamycin) activity, in liver transplant patient resulted in severe rhabdomyolysis.
In this study, we generated a zebrafish statin-induced myopathy model. At first, we compare the adverse effect induced by Simvastatin, Lovastatin and Atorvastatin in zebrafish. Then, we found that Simvastatin could induce visible muscle damage in zebrafish embryos, with degree of damage proportionate to Simvastatin concentration and length of exposure. We further investigated the effect of Rapamycin and Simvastatin co-treatment on zebrafish. Surprisingly, the results showed that the muscle toxicity induced by Simvastatin can be rescued by Rapamycin. To confirm this phenomenon is related to TOR signaling, we also knocked down the zebrafish TOR gene (ztor) using splicing morpholino. However, the morphants with reduced expression of TOR still demonstrated muscle damage upon Simvastatin administration, and the effect can be blocked by Rapamycin as well. These results indicate that Rapamycin may exert its protective effect against Simvastatin-induced myopathy via a TOR-independent mechanism. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T03:50:58Z (GMT). No. of bitstreams: 1 ntu-104-R01b46018-1.pdf: 1712227 bytes, checksum: 4db8ad6386e86911f4597a7194828c2c (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 摘要 ii
ABSTRACT iii 目錄 iv 圖目錄 vi 第一章 序言 1 1 膽固醇與血管疾病 1 2 Statins 1 3 Statins引起的肌肉病變 3 4 Rapamycin與TOR 5 5 以斑馬魚作為模式生物的優點 7 6 研究目的及策略 9 第二章 實驗材料與方法 11 1 實驗材料 11 2 實驗方法 12 第三章 實驗結果 25 1 Simvastatin使斑馬魚產生可見的肌肉病變 25 2 Simvastatin之濃度及處理時間與肌肉病變症狀呈正相關 25 3 以Rapamycin與Simvastatin共同處理降低肌肉病變症狀 26 4 Knockdown TOR對Simvastatin引起肌肉病變沒有影響 26 5 以Rapamycin對tor morphant處理能降低肌肉病變症狀 27 第四章 討論 28 參考文獻 31 附圖 44 附錄 51 | |
| dc.language.iso | zh-TW | |
| dc.subject | 人類疾病模式 | zh_TW |
| dc.subject | 他汀 | zh_TW |
| dc.subject | 斑馬魚 | zh_TW |
| dc.subject | 肌肉病變 | zh_TW |
| dc.subject | 雷帕黴素 | zh_TW |
| dc.subject | TOR | en |
| dc.subject | statins | en |
| dc.subject | Rapamycin | en |
| dc.subject | myopathy | en |
| dc.subject | zebrafish | en |
| dc.title | Statin引起斑馬魚肌肉病變之研究 | zh_TW |
| dc.title | Studies on statin-induced myopathy in zebrafish | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李明亭(Ming-Ting Lee),鄭嘉雄(Chia-Hsiung Cheng) | |
| dc.subject.keyword | 他汀,斑馬魚,肌肉病變,雷帕黴素,人類疾病模式, | zh_TW |
| dc.subject.keyword | statins,Rapamycin,TOR,zebrafish,myopathy, | en |
| dc.relation.page | 54 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-01-21 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科學研究所 | zh_TW |
| 顯示於系所單位： | 生化科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 未授權公開取用 | 1.67 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。